BR112014004251A2 - new crystal shape - Google Patents

new crystal shape

Info

Publication number
BR112014004251A2
BR112014004251A2 BR112014004251A BR112014004251A BR112014004251A2 BR 112014004251 A2 BR112014004251 A2 BR 112014004251A2 BR 112014004251 A BR112014004251 A BR 112014004251A BR 112014004251 A BR112014004251 A BR 112014004251A BR 112014004251 A2 BR112014004251 A2 BR 112014004251A2
Authority
BR
Brazil
Prior art keywords
new crystal
crystal shape
new
shape
abstract
Prior art date
Application number
BR112014004251A
Other languages
Portuguese (pt)
Inventor
Lee Mei-Yin
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BR112014004251A2 publication Critical patent/BR112014004251A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

resumo “nova forma de cristal” uma nova forma cristalina de um composto é mostrada.abstract “new crystal form” a new crystalline form of a compound is shown.

BR112014004251A 2011-09-01 2012-08-31 new crystal shape BR112014004251A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161530104P 2011-09-01 2011-09-01
PCT/EP2012/067027 WO2013030374A1 (en) 2011-09-01 2012-08-31 Novel crystal form

Publications (1)

Publication Number Publication Date
BR112014004251A2 true BR112014004251A2 (en) 2017-03-21

Family

ID=46829730

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014004251A BR112014004251A2 (en) 2011-09-01 2012-08-31 new crystal shape

Country Status (33)

Country Link
US (3) US9227953B2 (en)
EP (1) EP2751094B1 (en)
JP (1) JP6199291B2 (en)
KR (2) KR20190075172A (en)
CN (1) CN103906744A (en)
AU (2) AU2012300841C1 (en)
BR (1) BR112014004251A2 (en)
CA (1) CA2847066C (en)
CL (1) CL2014000489A1 (en)
CO (1) CO6890102A2 (en)
CR (1) CR20140098A (en)
CY (1) CY1120784T1 (en)
DK (1) DK2751094T3 (en)
DO (1) DOP2014000042A (en)
EA (1) EA027972B1 (en)
ES (1) ES2686563T3 (en)
HK (1) HK1198534A1 (en)
HR (1) HRP20181375T1 (en)
HU (1) HUE041578T2 (en)
IL (1) IL230977A (en)
LT (1) LT2751094T (en)
MA (1) MA35362B1 (en)
MX (1) MX349243B (en)
MY (1) MY172885A (en)
PE (1) PE20141411A1 (en)
PL (1) PL2751094T3 (en)
PT (1) PT2751094T (en)
RS (1) RS57644B1 (en)
SG (1) SG2014011886A (en)
SI (1) SI2751094T1 (en)
UA (1) UA114607C2 (en)
WO (1) WO2013030374A1 (en)
ZA (1) ZA201401176B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103906744A (en) 2011-09-01 2014-07-02 葛兰素集团有限公司 Novel crystal form
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
FR2634376B1 (en) 1988-07-21 1992-04-17 Farmalyoc NOVEL SOLID AND POROUS UNIT FORM COMPRISING MICROPARTICLES AND / OR NANOPARTICLES, AS WELL AS ITS PREPARATION
IT1227626B (en) 1988-11-28 1991-04-23 Vectorpharma Int SUPPORTED DRUGS WITH INCREASED DISSOLUTION SPEED AND PROCEDURE FOR THEIR PREPARATION
IT1243390B (en) 1990-11-22 1994-06-10 Vectorpharma Int PHARMACEUTICAL COMPOSITIONS IN THE FORM OF PARTICLES SUITABLE FOR THE CONTROLLED RELEASE OF PHARMACOLOGICALLY ACTIVE SUBSTANCES AND PROCEDURE FOR THEIR PREPARATION.
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
HUT70952A (en) 1992-06-10 1995-11-28 Eastman Kodak Co Surface modified nanoparticles based on nosteroidal inflammatory drugs, process for preparing them and pharmaceutical compns. contg. them
AU660852B2 (en) 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5587143A (en) 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5585108A (en) 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5569448A (en) 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5560931A (en) 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5571536A (en) 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5503723A (en) 1995-02-08 1996-04-02 Eastman Kodak Company Isolation of ultra small particles
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5622938A (en) 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5718919A (en) 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US5565188A (en) 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5747001A (en) 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
CH690264A5 (en) 1995-06-30 2000-06-30 Symphar Sa aminophosphonates substituted derivatives, their preparation process and their use for preparing pharmaceutical compositions.
GB9626615D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626616D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626536D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
WO1998035666A1 (en) 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
GB0024808D0 (en) * 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
WO2005113797A2 (en) 2004-04-16 2005-12-01 Glaxo Group Limited METHODS FOR DETECTING Lp-PLA2 ACTIVITY AND INHIBITION OF Lp-PLA2 ACTIVITY
WO2008140450A1 (en) * 2007-05-11 2008-11-20 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
EA018101B1 (en) 2007-05-11 2013-05-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Methods of treatment of skin ulcers
KR101461659B1 (en) 2007-05-11 2014-11-17 토마스 제퍼슨 유니버시티 Methods of treatment and prevention of neurodegenerative diseases and disorders
US20080279846A1 (en) 2007-05-11 2008-11-13 Thomas Jefferson University Methods of treatment and prevention of neurodegenerative diseases and disorders
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
JP2013537203A (en) 2010-09-20 2013-09-30 グラクソ グループ リミテッド Tricyclic compounds, production methods, and uses thereof
EP2649053B1 (en) 2010-12-06 2015-11-04 Glaxo Group Limited Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp-pla2
JP2013544854A (en) 2010-12-06 2013-12-19 グラクソ グループ リミテッド Compound
JP2013545792A (en) 2010-12-17 2013-12-26 グラクソ グループ リミテッド Methods for treating and preventing eye diseases
CN103906744A (en) * 2011-09-01 2014-07-02 葛兰素集团有限公司 Novel crystal form
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme

Also Published As

Publication number Publication date
SI2751094T1 (en) 2018-10-30
CL2014000489A1 (en) 2014-08-01
UA114607C2 (en) 2017-07-10
WO2013030374A1 (en) 2013-03-07
PT2751094T (en) 2018-10-19
PL2751094T3 (en) 2018-11-30
AU2016200492A1 (en) 2016-02-18
KR20190075172A (en) 2019-06-28
CY1120784T1 (en) 2019-12-11
CA2847066A1 (en) 2013-03-07
DK2751094T3 (en) 2018-08-20
SG2014011886A (en) 2014-05-29
MX2014002454A (en) 2014-04-10
EA201490536A1 (en) 2014-08-29
CA2847066C (en) 2019-04-30
MA35362B1 (en) 2014-08-01
JP6199291B2 (en) 2017-09-20
MY172885A (en) 2019-12-13
CR20140098A (en) 2014-05-06
US9227953B2 (en) 2016-01-05
US20160367544A1 (en) 2016-12-22
AU2012300841A1 (en) 2014-03-13
KR20140056297A (en) 2014-05-09
HRP20181375T1 (en) 2018-10-19
DOP2014000042A (en) 2014-08-31
US9682074B2 (en) 2017-06-20
IL230977A (en) 2016-08-31
MX349243B (en) 2017-07-18
AU2012300841C1 (en) 2016-02-18
IL230977A0 (en) 2014-03-31
HK1198534A1 (en) 2015-05-15
ES2686563T3 (en) 2018-10-18
NZ621315A (en) 2016-06-24
EP2751094A1 (en) 2014-07-09
AU2016200492B2 (en) 2017-04-20
EA027972B1 (en) 2017-09-29
CO6890102A2 (en) 2014-03-10
CN103906744A (en) 2014-07-02
EP2751094B1 (en) 2018-06-20
HUE041578T2 (en) 2019-05-28
RS57644B1 (en) 2018-11-30
US20160075685A1 (en) 2016-03-17
AU2012300841B2 (en) 2015-10-29
LT2751094T (en) 2018-11-12
US20140213613A1 (en) 2014-07-31
PE20141411A1 (en) 2014-10-29
US9694004B2 (en) 2017-07-04
ZA201401176B (en) 2015-12-23
JP2014525428A (en) 2014-09-29

Similar Documents

Publication Publication Date Title
CR20140042A (en) INDAZOLES
CR20130537A (en) HETEROCYCLIC COMPOUNDS AS INHIBITORS OF KINASES
EP2697713A4 (en) Management of background tasks
CR20140024A (en) METALOENZYM INHIBITING COMPOUNDS
UY34092A (en) NEW COMPOUNDS AS JAK INHIBITORS
DE112012004838A5 (en) Configuration of operating devices for lamps
CR20130539A (en) TRIAZOLOPIRIDINS
PL2760821T3 (en) Choline salt of an anti-inflammatory substituted cyclobutenedione compound
LTPA2020526I1 (en) Crystals of a 2-acylaminothiazole compound
CR20140094A (en) ETHYLENE DERIVATIVES
CR20140322A (en) NEW BENCIL SULFONAMIDE DERIVATIVES USEFUL AS MOGAT-2 INHIBITORS
ZA201308393B (en) Production of acetyl-coenzyme a derived compounds
CR20130475A (en) ETHYLENE DERIVATIVES
BR112014005877A2 (en) capsule to prepare a drink
CR20130597A (en) ISOXAZOLINS AS THERAPÈUTIC AGENTS
CO6761304A2 (en) New compounds of bezodioxole-piperazine
IN2014DN06192A (en)
BR112013024097A2 (en) diaphragm interface apparatus to improve cycle life of a diaphragm
CY1120784T1 (en) NEW CRYSTAL FORM
MX2011013676A (en) Crystalline form of pemirolast.
CR20130603A (en) NEW COMPOUNDS AS INHIBITORS OF DIACILGLICEROL
BR112013022521A8 (en) degradation of penicillin compounds
EA201790238A1 (en) CRYSTAL INHIBITORS BACE
EP2900240A4 (en) Crystalline form of a reverse transcriptase inhibitor
EA201400188A1 (en) METHOD OF OBTAINING CRYSTALLINE FORM I AGOMELATIN

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements